Note: This article is for educational purposes only and should not replace medical advice from a dermatologist or qualified healthcare professional.
Hidradenitis suppurativa, usually shortened to HS, is one of those conditions that sounds complicated because, frankly, it is. It is a chronic inflammatory skin disease that can cause painful bumps, abscesses, draining tunnels, and scarring, often in areas where skin rubs together, such as the armpits, groin, buttocks, and under the breasts. People sometimes mistake it for acne, boils, ingrown hairs, or “bad luck in skin form.” But HS is not caused by poor hygiene, and it is not contagious.
For many people, the biggest frustration is that hidradenitis suppurativa does not behave like a simple skin infection. Antibiotics may help some flares. Surgery may help remove stubborn tunnels or scarred areas. Lifestyle changes can support overall disease control. But for moderate-to-severe HS, inflammation is often the engine under the hood. That is where biologic treatments enter the story.
Biologics are targeted medicines designed to calm specific parts of the immune system. Instead of swinging a giant hammer at inflammation, they work more like a smart thermostat: they try to turn down certain inflammatory signals that are running too hot. For HS, biologics have changed the treatment conversation from “How do we survive the next flare?” to “How do we reduce flares, pain, drainage, and long-term damage?”
What Are Biologic Treatments for Hidradenitis Suppurativa?
Biologic treatments are medicines made from living cells or biological processes. In hidradenitis suppurativa, they are used to target immune pathways involved in chronic inflammation. Most biologics for HS are given by injection under the skin, though some biologic medicines in dermatology may also have intravenous options depending on the drug and condition.
The main keyword here is biologic treatments for hidradenitis suppurativa, but the real idea is simpler: these are advanced anti-inflammatory treatments for people whose HS is more than occasional mild bumps. They are usually considered when HS is moderate to severe, when symptoms keep returning, when tunnels or scarring are developing, or when other treatments have not provided enough relief.
Biologics do not “cure” HS. That would be lovely, and dermatologists everywhere would probably throw a parade. Instead, biologics aim to reduce inflammatory activity, decrease the number of abscesses and nodules, lower pain, improve drainage, and help patients gain better long-term control.
Why HS May Need Targeted Immune Treatment
HS is not just a blocked pore problem. Researchers now understand it as an inflammatory disease involving the hair follicle, immune signaling, bacteria, genetics, hormones, friction, smoking, metabolic health, and other factors. In some patients, inflammatory proteins such as tumor necrosis factor alpha, interleukin-17A, and interleukin-17F appear to play important roles.
That matters because older HS treatment plans often relied heavily on antibiotics. Antibiotics can still be useful, especially for reducing bacterial load and calming inflammation during certain flares. However, when HS is driven by ongoing immune overactivity, antibiotics alone may feel like putting a tiny umbrella over a thunderstorm. Helpful? Sometimes. Enough? Not always.
Biologic therapy gives dermatologists a more targeted option. By blocking selected inflammatory signals, biologics may help reduce the cycle of swelling, rupture, drainage, healing, and recurrence. This is especially important because repeated inflammation can lead to sinus tracts, rope-like scars, limited movement, odor concerns, sleep problems, and major quality-of-life disruption.
FDA-Approved Biologics for Hidradenitis Suppurativa
As of current U.S. treatment information, the main FDA-approved biologic options for hidradenitis suppurativa include adalimumab, secukinumab, and bimekizumab. Each works differently, and each has its own age approvals, dosing schedule, benefits, and safety considerations.
Adalimumab: The TNF-Alpha Blocker
Adalimumab is a tumor necrosis factor alpha inhibitor, often called a TNF inhibitor. TNF-alpha is an inflammatory protein involved in several immune-mediated diseases, including rheumatoid arthritis, Crohn’s disease, psoriasis, and hidradenitis suppurativa.
Adalimumab was the first biologic approved in the United States for moderate-to-severe HS. It is approved for patients 12 years of age and older with moderate-to-severe hidradenitis suppurativa. In clinical trials, including the well-known PIONEER studies, adalimumab helped more patients reach meaningful reductions in inflammatory nodules and abscesses compared with placebo.
In real life, adalimumab may be considered for someone who has recurring painful lesions, scarring, draining areas, or disease that affects daily comfort and function. For example, a person who has tried topical clindamycin, oral antibiotics, careful wound care, and friction reduction but still experiences repeated underarm and groin flares may be a candidate for a biologic discussion.
Adalimumab is usually self-injected at home after training. Many patients appreciate that it does not require frequent office visits once the routine is established. The less glamorous part is that it involves needles, insurance paperwork, storage instructions, and patience. Biologics are powerful tools, not instant magic wands with tiny capes.
Secukinumab: Targeting IL-17A
Secukinumab is an interleukin-17A inhibitor. IL-17A is another inflammatory signal involved in immune pathways connected to skin inflammation. Secukinumab is FDA approved for moderate-to-severe hidradenitis suppurativa in adults and pediatric patients 12 years of age and older.
Clinical evidence from the SUNSHINE and SUNRISE phase 3 trials showed that secukinumab improved signs and symptoms of moderate-to-severe HS and maintained benefit over longer follow-up. This approval was important because it gave patients and dermatologists a different biologic mechanism beyond TNF-alpha inhibition.
That different mechanism can matter. Some people do not respond well enough to one biologic. Others respond at first and then lose response over time. Some cannot use a specific biologic because of medical history, side effects, or other risk factors. Having another approved pathway is like adding another route on the map when the main road is blocked by construction, traffic, and a suspiciously slow-moving cement truck.
Bimekizumab: Targeting IL-17A and IL-17F
Bimekizumab is a newer biologic option for adults with moderate-to-severe hidradenitis suppurativa. It targets both IL-17A and IL-17F, two inflammatory proteins involved in immune signaling. The goal is to reduce inflammatory activity through dual IL-17 pathway inhibition.
The BE HEARD I and BE HEARD II phase 3 trials evaluated bimekizumab in adults with moderate-to-severe HS. Trial results showed meaningful improvement in HS clinical response compared with placebo, including improvements that were maintained through later parts of the studies. For patients who have lived through years of painful flares, “meaningful improvement” is not a small phrase. It can mean fewer days planning clothing around drainage, fewer canceled plans, and less fear of the next angry lump arriving like an uninvited guest.
Bimekizumab is approved for adults, and it is not currently described as a pediatric HS treatment. As with other biologics, patients need screening, monitoring, and a personalized risk-benefit discussion before starting.
How Doctors Decide Whether a Biologic Is Right for HS
A dermatologist usually considers several factors before recommending a biologic. These include disease severity, number and location of lesions, presence of draining tunnels, scarring, pain level, flare frequency, previous treatments, other medical conditions, pregnancy plans, infection history, and patient preferences.
Severity is often described using Hurley stages. Hurley Stage I generally means abscesses without tunnels or extensive scarring. Hurley Stage II involves recurrent abscesses with tunnels and scarring, usually separated by areas of normal skin. Hurley Stage III is more widespread, with interconnected tunnels and scarring across an area. Biologics are most often discussed in moderate-to-severe disease, especially when HS is affecting function, comfort, sleep, work, school, relationships, or mental health.
Doctors may also use scoring tools such as HiSCR, which stands for Hidradenitis Suppurativa Clinical Response. In simple terms, HiSCR measures whether inflammatory nodules and abscesses improve without worsening abscesses or draining tunnels. Patients do not need to memorize every scoring system, but knowing that dermatologists track objective improvement can make treatment feel less mysterious.
What to Expect Before Starting a Biologic
Before biologic therapy begins, the healthcare team typically reviews medical history and checks for infection risks. Screening may include tuberculosis testing and blood work. Depending on the medicine and patient history, doctors may also review hepatitis status, liver tests, vaccination history, inflammatory bowel disease history, and other immune-related conditions.
Patients should tell their doctor about frequent infections, chronic cough, unexplained weight loss, fevers, liver disease, immune system problems, cancer history, pregnancy, breastfeeding, planned surgery, and all medications or supplements they use. This is not the time to play “guess what I forgot to mention.” Biologics can be excellent treatments, but they require honest teamwork.
Vaccines are another important topic. Many clinicians prefer patients to be up to date on recommended vaccines before starting biologic therapy. Live vaccines may not be recommended during treatment with certain biologics, so timing matters. A dermatologist or primary care provider can help plan safely.
How Long Do Biologics Take to Work?
Some people notice improvement within weeks. Others need several months. A common evaluation window is around 12 to 16 weeks, though the timeline depends on the medication, dosing schedule, disease severity, and treatment goals. HS is stubborn, and biologics may need time to cool down inflammation that has been building for years.
Improvement may show up in several ways: fewer new nodules, less swelling, reduced drainage, less pain, shorter flares, better mobility, or longer periods between flare-ups. The first sign may not be dramatic. It may be something quietly wonderful, like realizing you wore jeans for a full day without regretting every life choice since breakfast.
If a biologic does not work well enough, the doctor may adjust the overall treatment plan. That may include checking adherence, reviewing injection technique, managing infections or tunnels, adding other therapies, changing biologics, or considering a surgical approach for persistent scarred areas.
Possible Side Effects and Safety Considerations
Biologics affect the immune system, so infection risk is a major safety topic. Patients should report signs of infection, fever, persistent cough, painful urination, unusual fatigue, open wounds that are worsening, or other concerning symptoms. Injection-site reactions such as redness, itching, swelling, or tenderness can also occur.
TNF inhibitors such as adalimumab carry warnings about serious infections and other rare but important risks. IL-17 inhibitors such as secukinumab and bimekizumab may have safety considerations related to infections and inflammatory bowel disease symptoms in some patients. Bimekizumab labeling also includes specific safety warnings that clinicians review carefully before prescribing.
The point is not to scare patients away from biologics. The point is to respect them. A biologic is not the same as a casual moisturizer you bought because the label said “calming” and had a leaf on it. These are prescription immune-targeting therapies that can be extremely helpful when used thoughtfully.
Biologics Are Often Part of a Bigger HS Treatment Plan
One common misconception is that starting a biologic means every other HS strategy disappears. In reality, HS care is usually layered. A dermatologist may combine biologic therapy with topical treatments, short courses of antibiotics, hormonal therapy, pain management, laser hair reduction, wound care, nutrition support, smoking cessation support, or surgery for chronic tunnels.
For example, a patient may start secukinumab to control inflammation but still need deroofing for an old tunnel that behaves like a tiny underground plumbing problem. Another patient may use adalimumab along with gentle cleansing, absorbent dressings, and weight-neutral friction reduction strategies. Someone else may respond to bimekizumab but still need help managing pain, fatigue, or the emotional burden of living with a visible and unpredictable condition.
Good HS care is not just about counting bumps. It is about helping a person move more comfortably, sleep better, feel less embarrassed, and stop organizing life around the possibility of a flare.
Questions to Ask Your Dermatologist About Biologics
Patients considering biologic treatment for hidradenitis suppurativa may want to ask practical questions. Which biologic fits my disease pattern? How soon should we expect improvement? What symptoms should I track? What screenings do I need? How will we know if it is working? What side effects should trigger a phone call? Can I take this with my current medicines? What happens if my insurance delays approval?
It also helps to ask about injection training, storage, travel, missed doses, copay programs, and follow-up visits. These details may sound boring, but they are the nuts and bolts of successful treatment. Nobody wants to discover at midnight that a refrigerated medication has been stored incorrectly next to leftover pizza and mystery soup.
Experience-Based Insights: What Living With Biologic Treatment Can Feel Like
People starting biologic treatments for hidradenitis suppurativa often describe a mix of hope, caution, and exhaustion. Hope comes from finally having a treatment that targets the inflammatory biology of HS. Caution comes from reading the safety information, which can make even brave people raise an eyebrow. Exhaustion comes from the long road many patients travel before getting an accurate diagnosis and an advanced treatment plan.
One common experience is the “waiting period.” A patient may take the first dose and secretly hope to wake up the next morning with calm skin and theme music. Usually, it is not that cinematic. Improvement may arrive gradually. A flare may be less intense than usual. A painful area may drain less. A person may go two weeks without a new lesion and wonder if they are imagining it. Tracking symptoms with photos, pain scores, drainage notes, and flare dates can help turn vague impressions into useful evidence.
Another experience is emotional adjustment. HS can train people to expect disappointment. When a biologic begins working, some patients feel relief, but also disbelief. They may continue dressing defensively, avoiding certain clothes, or canceling activities out of habit. Healing is not only physical; it also involves learning to trust the body a little more again.
Injection anxiety is also real. Some people adapt quickly. Others need time, coaching, numbing strategies, or help from a caregiver. Autoinjectors can make the process easier for many patients, but the first few doses may still feel dramatic. The best approach is practical: follow the exact training instructions, rotate injection sites as recommended, allow medication to reach the advised temperature if the instructions permit it, and create a calm routine. A small reward afterward is not childish. It is excellent project management.
Insurance and access can be another major part of the biologic experience. Prior authorization, specialty pharmacy calls, refill coordination, and copay questions can feel like a second disease made entirely of paperwork. Patients often benefit from keeping a folder with approval letters, pharmacy numbers, dose dates, lab results, and dermatologist notes. Organized documentation can save time when refills, appeals, or treatment changes are needed.
Social life may improve when HS becomes better controlled, but it may not happen instantly. Someone who has spent years worrying about odor, drainage, pain, or visible bandages may need time to feel comfortable dating, exercising, traveling, or wearing certain clothes again. Biologics may reduce disease activity, but confidence often returns in stages.
Finally, many patients learn that biologic treatment works best when paired with realistic expectations. A successful result may not mean perfect skin forever. It may mean fewer flares, less pain, shorter recovery time, fewer emergency visits, or the ability to work, study, parent, exercise, or sleep with less interruption. For HS, those wins are not small. They are life upgrades, and they deserve to be counted.
Conclusion
Biologic treatments for hidradenitis suppurativa have transformed the way moderate-to-severe HS can be managed. Adalimumab targets TNF-alpha, secukinumab targets IL-17A, and bimekizumab targets both IL-17A and IL-17F. These therapies are not cures, and they are not right for everyone, but they offer targeted options for people whose HS is driven by ongoing inflammation.
The best treatment plan is personal. It should account for disease severity, symptoms, medical history, safety risks, lifestyle, access, and patient goals. For some people, biologics can mean fewer painful flares and better daily control. For others, they may be one part of a broader plan that includes wound care, antibiotics, hormonal therapy, surgery, and supportive care.
HS can be relentless, but modern treatment is becoming more precise. For patients who have been told to “just wash better” or “stop worrying about boils,” biologic therapy offers a more accurate message: hidradenitis suppurativa is an inflammatory disease, and it deserves serious, science-based care.
